CAS: 1951431-22-3
Brand | Product data | Purity | Price range | Estimated delivery |
---|---|---|---|---|
BKI-1369 REF: 3D-BDD43122CAS: 1951431-22-3 | Min. 95% | To inquire | Mon 13 Jan 25 | |
BKI-1369 REF: TM-T10556CAS: 1951431-22-3 | - - - | 158.00 €~2,340.00 € | Tue 21 Jan 25 |
BKI-1369
CAS:1951431-22-3
BKI-1369 is an experimental drug in the class of benzimidazole derivatives that is being studied …
Formula:
C23H27N7O
Purity:
Min. 95%
Molecular weight:
417.51 g/mol
Ref: 3D-BDD43122
1mg | To inquire | ||
5mg | To inquire | ||
10mg | To inquire | ||
25mg | To inquire | ||
50mg | To inquire |
Estimated delivery in United States, on Monday 13 Jan 2025
BKI-1369
CAS:1951431-22-3
BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).
Formula:
C23H27N7O
Color and Shape:
Solid
Molecular weight:
417.51
Ref: TM-T10556
5mg | 444.00 € | ||
25mg | 1,410.00 € | ||
50mg | 1,854.00 € | ||
100mg | 2,340.00 € |
Estimated delivery in United States, on Tuesday 21 Jan 2025